- Residency - UT Southwestern Medical Center (2000-2004), Internal Medicine
- Fellowship - Johns Hopkins Hospital (2004-2007), Medical Oncology
- Medical School - Weill Cornell Graduate School of Medical Science (1996-2000)
David Gerber, M.D.
- Internal Medicine - Hematology/Oncology
- Chest Cancers
- Lung Cancer
He graduated cum laude from Yale University in New Haven, Conn., and earned his medical degree at Cornell University Medical College in New York.
He completed his internship and residency in internal medicine at UT Southwestern, followed by a fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore.
Dr. Gerber is board certified in internal medicine and medical oncology, and he holds medical licenses in both Texas and Maryland.
He is active in research related to lung cancer, including clinical trials. His research has generated more than 100 publications that he has authored or co-authored, including articles, abstracts, book chapters, book reviews, and invited manuscripts. His studies have contributed to invitations to lecture both nationally and
He serves on a number of committees at UT Southwestern, and he is an active participant on the American Society of Clinical Oncology’s Lung Cancer Education Committee and the International Association for the Study of Lung Cancer’s Career Development Committee. He also serves on the editorial board of the Journal of Clinical Oncology.
Dr. Gerber holds memberships in several professional organizations, and he has been honored with numerous awards, including being named a Best Doctor by D Magazine in 2018 and 2020.
Meet Dr. Gerber
Lung Cancer Specialist
UT Southwestern Medical Center medical oncologist David Gerber, M.D., specializes in treating patients with lung cancer – a disease from which more people die every year than colon, breast, and prostate cancer combined.
Dr. Gerber says he focuses on lung cancer because the disease is so common, and the specialty offers him an opportunity to help a lot of people.
“I get to develop relationships with patients and their families that are very special,” he says.
"I’m invested in helping patients have a better quality of life.”
Dr. Gerber, a D Magazine Best Doctor, believes his role as a medical oncologist extends beyond administering chemotherapy to providing psychosocial support, including offering methods to cope with the stress and difficulties that can come with a lung cancer diagnosis.
“Providing support throughout the process is a role that I cherish,” he says. “It is very important and rewarding for me.”
In addition to patient care, Dr. Gerber is very active in lung cancer research, including designing and overseeing clinical trials based on scientific discoveries made at UT Southwestern.
“In lung cancer, there are still many unanswered questions, which means there are many opportunities to make an impact on the disease,” he says.
Dr. Gerber is Co-Director of UT Southwestern’s Experimental Therapeutics Program, which aims to identify novel targets for tumor targeting, perform laboratory testing of new treatment strategies, and develop new biomarkers and clinical trials.
The Experimental Therapeutics Program is just one reason why Dr. Gerber takes pride in being a member of the UT Southwestern team. After completing his internship and residency here, he chose to return as a faculty member.
“It’s an institution that I’m proud to be part of. I don’t know a place that provides better lung cancer care in the entire country.”
- International Association for the Study of Lung Cancer (2008)
- American Society of Clinical Oncology (2004)
- D Magazine Best Doctor 2020
- Castle Connolly Top Doctors 2015-2018
- D Magazine Best Doctors in Dallas 2011-2018
- National Cancer Institute Clinical Investigator Team Leadership Award 2011
Targeted Therapies for Non-Small Cell Lung Cancer
David E. Gerber (2011), Oxford University Press
Apar K. Ganti, David E. Gerber (2014), Oxford University Press
- Targeted Therapies for Non-Small Cell Lung Cancer
Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR Annals of oncology : official journal of the European Society for Medical Oncology 2018 May
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ Lung cancer (Amsterdam, Netherlands) 2018 Mar 117 44-49
How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
Khan SA, Pruitt SL, Xuan L, Makris U, Gerber DE Lung cancer (Amsterdam, Netherlands) 2018 Jan 115 97-102
Cancer Center Clinic and Research Team Perceptions of Identity and Interactions.
Reimer T, Lee SJC, Garcia S, Gill M, Duncan T, Williams EL, Gerber DE Journal of oncology practice 2017 Oct JOP2017024349
Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines.
Ning N, Yan J, Dietrich MF, Xie XJ, Gerber DE Journal of oncology practice 2017 Oct JOP2017024299
Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity.
Garcia S, Bisen A, Yan J, Xie XJ, Ramalingam S, Schiller JH, Johnson DH, Gerber DE Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2017 Jul
Lung cancer diagnostic and treatment intervals in the United States: a health care disparity?
Yorio JT, Xie Y, Yan J, Gerber DE Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009 Nov 4 11 1322-30
Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.
Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Nov 17 21 6888-96
How Have We Diagnosed Early-Stage Lung Cancer without Radiographic Screening? A Contemporary Single-Center Experience.
Taiwo EO, Yorio JT, Yan J, Gerber DE PloS one 2012 7 12 e52313
Consent timing and experience: modifiable factors that may influence interest in clinical research.
Gerber DE, Rasco DW, Skinner CS, Dowell JE, Yan J, Sayne JR, Xie Y Journal of oncology practice / American Society of Clinical Oncology 2012 Mar 8 2 91-6
Stromal platelet-derived growth factor receptor a (PDGFRa) provides a therapeutic target independent of tumor cell PDGFRa expression in lung cancer xenografts.
Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Burns C, Brekken RA, Loizos N Molecular cancer therapeutics 2012 Nov 11 11 2473-82
Impact of prior cancer on eligibility for lung cancer clinical trials.
Gerber DE, Laccetti AL, Xuan L, Halm EA, Pruitt SL Journal of the National Cancer Institute 2014 Nov 106 11
Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.
Gerber DE, Hao G, Watkins L, Stafford JH, Anderson J, Holbein B, Öz OK, Mathews D, Thorpe PE, Hassan G, Kumar A, Brekken RA, Sun X American journal of nuclear medicine and molecular imaging 2015 5 5 493-503
Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.
Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE Journal of the National Cancer Institute 2015 Apr 107 4
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, Priddy LL, Vo P, Dowell JE, Sarode V, Leff R, Meek C, Xie Y, Schiller JH Lung cancer (Amsterdam, Netherlands) 2015 Oct
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options.
Khan SA, Pruitt SL, Xuan L, Gerber DE JAMA oncology 2016 Jun
- Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
- Oncology outcomes research
- Lung cancer, clinical and translational research
- Chest Cancers
- Lung Cancer
- Medical Treatment of Lung Cancer
Q&A by Dr. Gerber
Articles by Dr. Gerber
Showing 1 locations